Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

not_yet_recruiting3100%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_1

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

NCT07227285
not_yet_recruiting

The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China

NCT06586801
not_yet_recruitingnot_applicable

Impact of Age-related Macular Degeneration on Daily Living Activitie

NCT06333873

Clinical Trials (3)

Showing 3 of 3 trials
NCT07227285Phase 1

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Not Yet Recruiting
NCT06586801

The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China

Not Yet Recruiting
NCT06333873Not Applicable

Impact of Age-related Macular Degeneration on Daily Living Activitie

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3